The escalating global burden of cancer, with a near 40% mortality increase over four decades and a projected 60% surge this decade, culminating in an estimated 13 million deaths by 2030, underscores the urgent need for improved therapies. Colorectal cancer (CRC), the third most frequent malignancy and second leading cause of cancer mortality worldwide, accounting for approximately 10% of diagnoses, necessitates innovative treatment strategies. This in vitro study investigated the effects of combined exposure to 5-fluorouracil (5-FU) and 5-Aza cytidine (5-Aza) on human colorectal carcinoma cells (HCT116). Employing MTT, wound healing, and colony formation assays, we observed significant reductions in cell viability, migration, and proliferation with the combined treatment compared to monotherapies. Whole-exome sequencing (WES) revealed a substantial decrease in the number and diversity of single-nucleotide polymorphisms (SNPs) in 5-FU-treated cells. These findings demonstrate that combined 5-Aza/5-FU exposure alters HCT116 cellular responses; however, formal pharmacological synergy cannot be inferred from the present experimental design. The synergistic effect of 5-Aza sensitized CRC cells to 5-FU.
A thyroid nodule is characterized as a discrete lesion, distinguishable from the adjacent thyroid parenchyma, and is frequently encountered in clinical settings. Currently, the terminology "nodular disease of the thyroid" is advised for use in both clinical and pathological classifications due to its expansiveness. Individuals with longstanding multinodular goitres are at risk for cystic degeneration, haemorrhaging, and dystrophic calcification. The main aim of this report is to assess the potential risk of cancer, mitigate the chances of obstructive symptoms and formulate a strategy for a secure and efficient surgical procedure. This paper presents a case involving a 68-year-old female patient who reported an anterior neck mass persisting for 35 years. Clinical assessments, imaging studies, and pathological examinations indicated extensive calcification within a giant nodular thyroid disease, which exerted pressure on the colloid goitre, reducing it to a thin peripheral layer without atypical features. The distinct contribution of this case is the emphasis on the uncommon nature of this presentation, and the associated diagnostic uncertainty, despite the presence of extensive macrocalcification, which still raises concerns about malignancy and necessitates thorough examination. Additionally, it underscores the notable surgical difficulties posed by the density, size, and potential adherence of the calcified tissue to adjacent structures. Key clinical insights reveal that imaging plays a vital role in surgical planning, that the prevention or alleviation of symptoms is an important outcome and that histopathological analysis remains the gold standard for diagnosis. The occurrence of extensive calcification in such a condition is uncommon. Effective collaboration among clinicians, radiologists, and pathologists is essential for accurate diagnosis and informed decision-making regarding thyroid nodular disease. Early diagnosis and intervention for nodular thyroid conditions are advocated, as advancing lesions may lead to compressive complications.
Intestinal obstruction is a significant medical condition marked by an impediment in the bowel’s capacity to eliminate waste. This condition is characterized by a blockage that hinders digestion and the regular expulsion of waste, which can be attributed to either functional or mechanical factors. A malignant bowel obstruction is frequently observed as a complication in advanced cancer cases, particularly those affecting the digestive tract. A 59 year old male presented with a one-month history characterized by infrequent bowel movements, abdominal distension and pain. Following a comprehensive clinical and imaging studies, a diagnosis of intestinal obstruction was established. The presence of a colonic tumour located in the proximal segment of the ascending colon and caecum, accompanied by a significantly dilated caecum displaying an incompetent ileo-caecal valve and a distended ileum, constituted the indication for a right hemicolectomy. The postoperative course was unremarkable. Ultimately, histopathological analysis confirmed a definitive diagnosis of colon adenocarcinoma. Colonic cancer situated in the proximal ascending colon and the adjacent caecum is uncommon and may manifest as an intestinal obstruction. In appropriate circumstances, right hemicolectomy is considered the preferred therapeutic approach. Early detection and intervention which can be enhanced through targeted screening, are advisable to avert the complications associated with advanced colonic tumours.
Introduction: This study investigates the molecular and biophysical changes in Tumor-Associated Macrophage (TAM)-derived exosomes (TAME) compared to exosomes from non-tumor microenvironment (TE) macrophages (MO-E). TAMs are immune cells infiltrating tumors that promote cancer progression. Materials and Methods: Characterizing the cargo of TAME via Next Generation RNA Sequencing protein microarray analysis and studying their morphological and nanomechanical properties using Atomic Force Microscopy (AFM). Results: Key Findings regarding Morphology showed TAME are significantly smaller (~50.6 nm) than MO-E (~64.8 nm). TAME exhibit higher Young's modulus (~15.5 MPa) indicating increased stiffness. Surface roughness ot TAME Is slightly higher (~3.64 nm) than MO-E (~3.51 nm). RNA sequencing revealed differential expression of genes involved in drug metabolism, cell cycle regulation, survival pathways, and immune modulation. Pathways such as NF-KB, PI3K/Akt, IL-13 signaling, and metabolic reprogramming are influenced by TAME cargo. Proteomics studies showed several Top upregulated proteins include ORP150 (promotes VEGF secretion), CSRP1, C1qB, DNER, PEPD, with roles in tumor growth and metastasis. Downregulated proteins include tumor suppressors like GOLPH2 and VNN1. These protein profiles suggest TAME carry oncoproteins that support tumor proliferation, invasion, and immune evasion. Conclusion: This study demonstrates that TAM-derived exosomes are morphologically distinct and carry molecular cargo that modulates key cancer-related pathways, highlighting their potential as biomarkers and therapeutic targets. The significance lies in understanding TAME's role in cancer progression, which could lead to novel diagnostic biomarkers and therapeutic targets, especially considering current limitations in cancer diagnosis accuracy.
Development of colorectal cancer (CRC) is a slow process, where a benign polyp progresses into a malignant stage over a long period of time. The patient may be asymptomatic during this period, thus delayed diagnosis has become a prime obstacle in managing CRC. Improved routine screening for early detection and prognosis will aid in better management of CRCs reducing mortality rates. Diagnosis of CRCs is primarily based on the invasive colonoscopy and tissue biopsy and fecal occult blood test with alongside evaluation of carcinoembryonic antigen (CEA) levels in blood for prognosis and recurrence. However, CEA as a standalone biomarker for CRCs, fail due to its non-specificity, low sensitivity and high false-positivity highlighting the importance of identification of new biomarkers for CRCs. In the recent past inflammatory cytokines emerged as key drivers of CRC pathogenesis, particularly as determinants of disease progression. The pleiotropic cytokine, interleukin-6 (IL-6) has been identified as activating oncogenic gene transcription in the colorectal epithelial cells leading to the pathogenesis of CRCs. By activating STAT3 signaling pathway, IL-6 promotes initiation, growth and metastasis of the colorectal cancer cell clone. In this review, we present the prospect of IL-6 in CRCs, describing the emerging evidence for IL-6 as a potential biomarker, the drawbacks of IL-6 and future directions for IL-6 as a diagnostic and prognostic marker for CRC. The original articles were extracted from the PubMed using the key words: "IL-6/interleukin 6 levels in colorectal cancer/ IL-6/ interleukin 6 concentrations in colorectal cancer/ IL-6 expression/ serum interleukin 6/ IL-6 in colorectal cancer". Full text articles published in English in last 25 years (from 2000 to July 2025) were included and the research carried out in animal models and in vitro, reviews, case reports, meta-analyses, editorials and non-relevant articles (post –surgery/treatment, studies on IL-6 in overlapping cancers/conditions etc.) were excluded. Though IL-6 stands as a potential marker for CRCs with markedly elevated levels, heterogeneity of patient populations with inadequacy of data for defining and distinguishing clinical sub groups, control groups and methodologies have become a barrier for its progression from bench to bed side. Hence, prospective research need to be focused on obtaining data on IL-6 using standardized methodologies to determine stage-specific and population specific cut-off values in well-defined CRC sub groups.
